When was Xcell Biosciences founded?

Xcell Biosciences was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is Xcell Biosciences located?

Xcell Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco,California.

Who is the current CEO of Xcell Biosciences?

Brian Feth of Xcell Biosciences.

How many employees does Xcell Biosciences have?

As of Jul 31, 2026, the latest employee count at Xcell Biosciences is 16.

Is Xcell Biosciences a funded company?

Xcell Biosciences is a funded company, having raised a total of $40.9M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 30, 2015.

When was the latest funding round of Xcell Biosciences?

Xcell Biosciences' latest funding was a $***** Series B round on Dec 06, 2024, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.9B in funding in 2026 to date.

Where does Xcell Biosciences rank among its competitors?

Xcell Biosciences ranks 22nd amongst 467 active competitors, of which 154 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Bio, which secured an undisclosed amount in Aug, 2025.

Who are the top competitors of Xcell Biosciences?

Xcell Biosciences' top competitors include 10X Genomics, Geneoscopy and Caris Life Sciences. Among them, Mission Bio secured the most recent funding round in August, 2025.

Xcell Biosciences - 2026 Company Profile, Team, Funding & Competitors

Xcell Biosciences is a series B company based in San Francisco (United States), founded in 2012 by James Lim and Brian Feth. It operates as a Developer of cell culture analysis device for cancer research. Xcell Biosciences has raised $40.9M in funding from Casdin Capital and HBM Genomics. The company has 467 active competitors, including 154 funded and 96 that have exited. Its top competitors include companies like 10X Genomics, Geneoscopy and Caris Life Sciences.

Company Details

Developer of cell culture analysis device for cancer research. The platform technology Avatar mimics in vivo physiological conditions for reproducible and more accurate in vitro tests. It allows for the preferential isolation and expansion of circulating tumor cells in the patient's blood. The company also provides cell-binding substrates and culture media to use in conjunction with its platform. The company has developed a cell analysis tool which is AI enables and assists with real-time analysis of cell health for identifying cell kinetics, targets, and other immunotherapy research.

Website: www.xcellbio.com/
Social
Email ID: *****@xcellbio.com
Phone Number: +1 **********
Registered Address: San Francisco,California

Key Metrics

Founded Year

2012

Location

San Francisco, United States

Stage

Series B

Total Funding

$40.9M in 4 rounds

Latest Funding Round

Series B, Dec 06, 2024, $*****

Investors

Casdin Capital & 11 more

Ranked

22^nd among 467 active competitors

Employee Count

16 as on Jul 31, 2026

Similar Companies

10X Genomics & 624 more

View Xcell Biosciences' full profile

Xcell Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Xcell Biosciences Inc. CIN: 455565377 , United States, Active	Dec 31, 1999	-	19 (As on Dec 31, 2024)	-

Xcell Biosciences has raised a total funding of $40.9M over 4 rounds. Its first funding round was on Jul 30, 2015. Xcell Biosciences has 12 institutional investors.

Here is the list of recent funding rounds of Xcell Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 06, 2024	1873770	Series B	8285235	9364208	6636047	6123882
Jan 19, 2022	9826948	Series B	5742531	7740852	1125996	Dynamk Capital & 4 more
Feb 16, 2017	5930619	Series A	5007433	4893255	HBM Genomics	5504679

Access funding benchmarks and valuations. Sign up today!

View details of Xcell Biosciences's funding rounds and investors

The founders of Xcell Biosciences are James Lim and Brian Feth.

Here are the details of Xcell Biosciences' key team members:

James Lim: Co-Founder & CSO of Xcell Biosciences. They serve on the boards of 2 companies.
Contact Info: 1 email address
Brian Feth: Co-Founder & CEO of Xcell Biosciences. They serve on the board of 1 company.
Contact Info: 1 email address

Xcell Biosciences' Board of Directors

Xcell Biosciences's board has 5 active members. Saeid Akhtari, James Lim, Brian Feth, Kaz Ohno and Brian S. Feth are independent board members.

Here is the list of Xcell Biosciences' board of directors:

Name	Type	Representing	Status	Duration
Saeid Akhtari	Independent board member	-	Current	9y 6m
pnxa{zf	Independent board member	-	Current	9y 2m
dtowtrg	Independent board member	-	Current	3y 7m
azgmvww	Independent board member	-	Current	4y 1m
zhpmbpz	Independent board member	-	Current	1y 4m

View details of Xcell Biosciences's Founder profiles and Board Members

Xcell Biosciences' employee count trend

Xcell Biosciences has 16 employees as of Jul 26. Here is Xcell Biosciences's employee count trend over the years:

Employee count trend for Xcell Biosciences

Uncover Xcell Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xcell Biosciences include 10X Genomics, Geneoscopy and Caris Life Sciences. Here is the list of Top 10 competitors of Xcell Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	10X Genomics 2012, Pleasanton (United States), Public	Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis	$243M	Fidelity Investments, Meritech & 14 others	77/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
5th	Mission Bio 2014, San Francisco (United States), Series C	Provider of single cell multiomics platform for genotypic and phenotypic analysis	$120M	Ally Bridge Group, Novo Holdings & 29 others	65/100
6th	Atrandi Biosciences 2016, Vilnius (Lithuania), Series A	A life sciences tool company transforming single-cell research with its patented Semi-Permeable Capsule(SPC) technology, enabling high-throughput and multi-step workflows	$31M	Lux Capital, VSquared Ventures & 4 others	64/100
7th	LUMICKS 2014, Amsterdam (Netherlands), Series D	Manufacturer of optical tweezers for single molecule analysis instruments	$93.4M	Farallon Capital Management, Lauxera Capital Partners ... & 11 others	63/100
8th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
9th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
22nd	Xcell Biosciences 2012, San Francisco (United States), Series B	Developer of cell culture analysis device for cancer research	$40.9M	PavLyfe, DST Global & 10 others	59/100